Gsk-256066

CAS No.

801312-28-7

MDL No.

MFCD18206923

C₂₇H₂₆N₄O₅S

518.60

InChI Key

JFHROPTYMMSOLG-UHFFFAOYSA-N

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Pack Size

Purity

Price

Availability

Action

On Request

Custom synthesis and bulk supply options are available upon request.

Product Information

GSK-256066 has been used in trials studying the treatment and diagnosis of SAR, asthma, mild asthma, allergic rhinitis, and seasonal allergic rhinitis, among others.

CAS No.	801312-28-7
Product Name	Gsk-256066

Biological Targets

PDE4A·PDE4D·PDE4B·PDE4C

Associated Conditions

seasonal allergic rhinitis·chronic obstructive pulmonary disease·asthma

* The information provided here is compiled from public sources and is for reference only.

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Documentation

Gsk-256066

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Related Articles

GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.

In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor.

The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma.

Documentation

Similar Products

3-(3-Carbamoyl-4-(3-methoxyphenylamino)-8-methylquinolin-6-ylsulfonyl)benzoic acid